Patents by Inventor Birgitta Olsson
Birgitta Olsson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170049716Abstract: The invention relates to nitisinone (2-[2-nitro-4-(trifluoromethyl)benzoyl]-1,3-cyclohexanedione) for use in the treatment of alkaptonuria, wherein nitisinone is administered in a dose of at least 4 mg per day. The invention also relates to a pharmaceutical composition comprising nitisinone for use in the treatment of alkaptonuria, wherein nitisinone is administered in a dose of at least 4 mg per day.Type: ApplicationFiled: April 29, 2015Publication date: February 23, 2017Applicant: Swedish Orphan Biovitrum International ABInventor: Birgitta Olsson
-
Publication number: 20150297683Abstract: The present invention relates to a method to increase the absorption by a human infant of at least one unsaturated fatty acid, said method comprising the enteral administration to said infant of recombinant human bile-salt-stimulated lipase (rhBSSL). In another aspect the invention also relates to a method to improve the visual and/or cognitive development of a human infant, said method comprising the enteral administration to said infant of rhBSSL. Such methods have particular utility for preterm human infants, particular those in medical need of increasing their absorption of or availability to such unsaturated fatty acids. In further aspects, the invention relates to kits, packaged-pharmaceutical-products, recombinant human bile-salt-stimulated lipase and pharmaceutical compositions, in each case useful for increasing the absorption by a human infant of at least one unsaturated fatty acid, or for increasing the visual and/or cognitive development of a human infant.Type: ApplicationFiled: March 12, 2015Publication date: October 22, 2015Inventors: Olle HERNELL, Birgitta OLSSON, Patrik STROMBERG, Lennart SVENSSON, Kristina TIMDAHL, Marten VAGERO, Maria OHMAN
-
Publication number: 20150283215Abstract: The present invention relates to a method to increase the growth velocity of a human infant, said method comprising the enteral administration to said infant of recombinant human bile-salt-stimulated lipase (rhBSSL). Such method has particular utility for underweight or preterm human infants, particular those in medical need of increasing their growth velocity. The invention also relates to compositions, including infant feeds, kits, packaged-pharmaceutical-products and pharmaceutical compositions, and also to methods to prepare infant feeds.Type: ApplicationFiled: March 12, 2015Publication date: October 8, 2015Inventors: Olle HERNELL, Birgitta OLSSON, Patrik STROMBERG, Lennart SVENSSON, Kristina TIMDAHL, Marten VAGERO, Maria OHMAN
-
Patent number: 8986682Abstract: The present invention relates to a method to increase the absorption by a human infant of at least one unsaturated fatty acid, said method comprising the enteral administration to said infant of recombinant human bile-salt-stimulated lipase (rhBSSL). In another aspect the invention also relates to a method to improve the visual and/or cognitive development of a human infant, said method comprising the enteral administration to said infant of rhBSSL. Such methods have particular utility for preterm human infants, particular those in medical need of increasing their absorption of or availability to such unsaturated fatty acids. In further aspects, the invention relates to kits, packaged-pharmaceutical-products, recombinant human bile-salt-stimulated lipase and pharmaceutical compositions, in each case useful for increasing the absorption by a human infant of at least one unsaturated fatty acid, or for increasing the visual and/or cognitive development of a human infant.Type: GrantFiled: October 21, 2011Date of Patent: March 24, 2015Assignee: Swedish Orphan Biovitrum AB (publ)Inventors: Olle Hernell, Birgitta Olsson, Patrik Strömberg, Lennart Svensson, Kristina Timdahl, Mårten Vågerö, Maria Öhman
-
Patent number: 8986759Abstract: The present invention relates to a method to increase the growth velocity of a human infant, said method comprising the enteral administration to said infant of recombinant human bile-salt-stimulated lipase (rhBSSL). Such method has particular utility for underweight or preterm human infants, particular those in medical need of increasing their growth velocity. The invention also relates to compositions, including infant feeds, kits, packaged-pharmaceutical-products and pharmaceutical compositions, and also to methods to prepare infant feeds.Type: GrantFiled: October 21, 2011Date of Patent: March 24, 2015Assignee: Swedish Orphan Biovitrum AB (pub)Inventors: Olle Hernell, Birgitta Olsson, Patrik Strömberg, Lennart Svensson, Kristina Timdahl, M{hacek over (a)}rten Vågerö, Maria Öhman
-
Publication number: 20120100127Abstract: The present invention relates to a method to increase the absorption by a human infant of at least one unsaturated fatty acid, said method comprising the enteral administration to said infant of recombinant human bile-salt-stimulated lipase (rhBSSL). In another aspect the invention also relates to a method to improve the visual and/or cognitive development of a human infant, said method comprising the enteral administration to said infant of rhBSSL. Such methods have particular utility for preterm human infants, particular those in medical need of increasing their absorption of or availability to such unsaturated fatty acids. In further aspects, the invention relates to kits, packaged-pharmaceutical-products, recombinant human bile-salt-stimulated lipase and pharmaceutical compositions, in each case useful for increasing the absorption by a human infant of at least one unsaturated fatty acid, or for increasing the visual and/or cognitive development of a human infant.Type: ApplicationFiled: October 21, 2011Publication date: April 26, 2012Applicant: SWEDISH ORPHAN BIOVITRUM AB (publ)Inventors: Olle Hernell, Birgitta Olsson, Patrik Strömberg, Lennart Svensson, Kristina Timdahl, Mårten Vågerö, Maria Öhman
-
Publication number: 20120100126Abstract: The present invention relates to a method to increase the growth velocity of a human infant, said method comprising the enteral administration to said infant of recombinant human bile-salt-stimulated lipase (rhBSSL). Such method has particular utility for underweight or preterm human infants, particular those in medical need of increasing their growth velocity. The invention also relates to compositions, including infant feeds, kits, packaged-pharmaceutical-products and pharmaceutical compositions, and also to methods to prepare infant feeds.Type: ApplicationFiled: October 21, 2011Publication date: April 26, 2012Applicant: SWEDISH ORPHAN BIOVITRUM AB (publ)Inventors: Olle Hernell, Birgitta Olsson, Patrik Strömberg, Lennart Svensson, Kristina Timdahl, Mårten Vågerö, Maria Öhman
-
Patent number: 6770295Abstract: The present invention is drawn to a method of treating an unstable or overactive urinary bladder by treating the patient with tolterodine or a tolterodine-related compound, or pharmaceutically acceptable salt thereof, with a controlled release formulation that maintains a substantially constant serum level of the active moiety or moieties for at least 24 hours. The present invention is further drawn to a formulation for the method.Type: GrantFiled: August 9, 2000Date of Patent: August 3, 2004Assignee: Pharmacia ABInventors: Bo Kreilgård, Lene Orup Jacobsen, Ulla Hoeck, Helle Kristensen, Torkel Gren, Lisbeth Nilvebrant, Anders Ringberg, Martin Wikberg, Bengt Hallén, Birgitta Olsson, Jan Strömbom
-
Patent number: 6630162Abstract: The invention relates to a pharmaceutical formulation containing tolterodine or a tolterodine-related compound, or a pharmacologically acceptable salt thereof, as active ingredient, in which the formulation exhibits a controlled in vitro release of the active ingredient in phosphate buffer at pH 6.8 of not less than about 80% after 18 hours, and after oral administration to a patient is capable of maintaining a substantially constant serum level of the active moiety or moieties for 24 hours. The invention also relates to the use of the pharmaceutical formulation for treating overactive bladder and gastrointestinal disorders.Type: GrantFiled: November 9, 2000Date of Patent: October 7, 2003Assignee: Pharmacia ABInventors: Lisbeth Nilvebrant, Bengt Hallen, Birgitta Olsson, Jan Strombom, Torkek Gren, Anders Ringberg, Martin Wikberg
-
Patent number: 5952005Abstract: An oral pharmaceutical preparation containing a therapeutically effective amount of a salt of morphine for administration once daily is provided. The preparation contains particles which have a core containing a salt of morphine coated with a barrier layer. The barrier layer is formed from a coating liquid that contains at least one water insoluble barrier forming component selected from the group consisting of ethyl cellulose, copolymers of acrylic and methacrylic esters and natural or synthetic waxes, and a plasticizer. The mean serum concentration of morphine obtained is at least 50% of the maximum serum concentration during at least 12 hours after the administration of a single dose of the preparation.Type: GrantFiled: April 21, 1997Date of Patent: September 14, 1999Assignee: Pharmacia & Upjohn AktiebolagInventors: Birgitta Olsson, Maritta Anneli Pesonen, Gert Ragnarsson
-
Patent number: 5656291Abstract: A method for manufacturing an oral controlled release pharmaceutical preparation in the form of a capsule containing a plurality of coated particles comprising a therapeutically effective amount of a salt of morphine coated with a barrier membrane providing a controlled, preferably pH-independent, release of morphine in that the serum concentration of morphine obtained is at least 50% of the maximum serum concentration during at least 12 hours after administration of a single dose, comprising spray coating the morphine containing particles with a coating liquid and drying.Type: GrantFiled: April 21, 1995Date of Patent: August 12, 1997Assignee: Pharmacia & Upjohn AktiebolagInventors: Birgitta Olsson, Maritta Anneli Pesonen, Gert Ragnarsson
-
Patent number: 5614218Abstract: An oral controlled release pharmaceutical preparation in the form of a tablet, capsule or sachet containing a plurality of coated particles comprising a therapeutically effective amount of a salt of morphine coated with a barrier membrane providing a controlled, preferably pH-independent, release of morphine in that the serum concentration of morphine obtained is at least 50% of the maximum serum concentration during at least 12 hours after administration of a single dose, and providing a significantly reduced plasma concentration fluctuation compared to known morphine preparations. A method for the manufacture of such a preparation and the use of such preparations for the manufacture of an analgesic useful in the treatment of severe chronicle pain are also provided.Type: GrantFiled: March 16, 1994Date of Patent: March 25, 1997Assignee: Pharmacia & Upjohn AktiebolagInventors: Birgitta Olsson, Maritta A. Pesonen, Gert Ragnarsson
-
Patent number: D577417Type: GrantFiled: February 12, 2008Date of Patent: September 23, 2008Assignee: Torso Innovation ABInventor: Birgitta Olsson